Prediction of hepatic clearance in human from in vitro data for successful drug development.
about
An update on the role of intestinal cytochrome P450 enzymes in drug dispositionCharacterization of gastrointestinal absorption of digoxin involving influx and efflux transporter in rats: application of mdr1a knockout (-/-) rats into absorption study of multiple transporter substrateIn vitro platforms for evaluating liver toxicity.Drug structure-transport relationshipsMetabolism-directed structure optimization of benzimidazole-based Francisella tularensis enoyl-reductase (FabI) inhibitors.Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability.Metabolism of oxycodone in human hepatocytes from different age groups and prediction of hepatic plasma clearance.Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactorMicroengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies.Applications of human pharmacokinetic prediction in first-in-human dose estimationHuman hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.Applications of minimal physiologically-based pharmacokinetic models.Selection of suitable prodrug candidates for in vivo studies via in vitro studies; the correlation of prodrug stability in between cell culture homogenates and human tissue homogenatesApplicability of the Rayleigh equation for enantioselective metabolism of chiral xenobiotics by microsomes, hepatocytes and in-vivo retention in rabbit tissues.Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human HepatocytesRitonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.Prediction of nanoparticle prodrug metabolism by pharmacokinetic modeling of biliary excretion.Benzimidazole analogs as potent hypoxia inducible factor inhibitors: synthesis, biological evaluation, and profiling drug-like propertiesKnowledge-driven approaches for the guidance of first-in-children dosing.The effects of obesity on drug pharmacokinetics in humans.Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results.In vitro-in vivo extrapolation (IVIVE) for predicting human intestinal absorption and first-pass elimination of drugs: principles and applications.Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics.An evaluation of the latest in vitro tools for drug metabolism studies.The role of drug metabolizing enzymes in clearance.Discovery and preclinical development of new antibiotics.The Universally Unrecognized Assumption in Predicting Drug Clearance and Organ Extraction Ratio.Predictions of bisphenol A hepatic clearance in the isolated perfused rat liver (IPRL): impact of albumin binding and of co-administration with naproxen.Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In VitroIbrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies.Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity.How to Choose In Vitro Systems to Predict In Vivo Drug Clearance: A System Pharmacology Perspective.A microfluidic hepatic coculture platform for cell-based drug metabolism studies.Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytesPrediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors.The use of isolated enterocytes to study Phase I intestinal drug metabolism: validation with rat and pig intestine.Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation.To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics.Utilization of Liver Microsomes to Estimate Hepatic Intrinsic Clearance of Monoamine Oxidase Substrate Drugs in Humans.
P2860
Q28079725-0AEE0E6C-0DD7-46BB-94B5-2D83D64F0DEFQ28577650-A7E086AB-62E6-45C2-9F6F-A2F44F6188A2Q34143314-46A9F9F7-2FF0-4041-A537-7EC43B82E8A9Q34420259-61860188-E541-44A2-8AEA-88CB308D4060Q35166429-2250502A-605F-4CE8-8791-3A2DFD10EFC2Q35264818-A5B9A29E-5B7B-4AA3-AC66-1E62CF238DA6Q35653564-AAED49F1-A44C-473C-97B9-70E7B0B5CDB3Q35745230-A15EDC11-5350-46AC-882A-BAF0AD19B148Q35826421-FBFD8827-9AE1-4F62-B011-B16833BD82CAQ35888391-FECD2F98-DFDF-4DCA-94E8-A4F6486B28C9Q36243653-45CE4DF3-875A-4715-8B1B-6B9940E53EEEQ36517093-A7CFA916-259C-4A91-9DFB-AFCE2A4DF108Q36631747-ADBA4557-EF08-4E8C-84E9-8CAF612FCB71Q36735906-75E17605-5DE8-4558-98ED-0E2AEF2BA5B4Q36947707-510C260F-2D8C-4B05-BA22-502812DF8CF5Q37193103-04ABB247-341C-4D32-B460-7AE98B6C1D1AQ37210032-D4067770-38E1-4A9D-BDCB-2101260B5BCAQ37694333-BBBE3E8D-8431-403F-B871-28A662F9605FQ37815555-1F1D32D0-DCA0-4B4E-9F3A-43EC1C1128FEQ37854751-B88ACCB0-23C5-4D3D-8577-49E6BA98602BQ38016204-EA2E99E4-C1B9-4A1F-9A47-21B7C40DA233Q38131859-060011D5-0AD9-48CF-A8B7-86B82F67DC97Q38151571-13BFB879-AE13-47CE-9132-B16DB00AE155Q38160881-4BD1E8A2-7914-46B2-9279-903B5465948AQ38176051-47F561D1-95D1-43AD-BF26-2A823DCFDEE1Q38197284-568176B0-51DB-4EC6-9103-19A9A0A1A5E1Q38649844-C13EC70C-B902-4CE6-BBFB-09C8D404D2EFQ38918303-AFD7DC54-6EDC-4683-A1E1-35ADF1294D0CQ38963389-35CC7E41-087A-4469-A675-A6CB898F44B8Q39639310-9632D08E-B1DA-44F3-AE74-E3742D3DFC30Q39666574-96D9ED74-1E2C-48F2-9CE8-673E1FDF0ED9Q39760801-4647BB98-1011-47AF-810E-3AB21597AD09Q40353496-57292D5F-D17C-4E51-BFDB-8EE966FEEE84Q41845201-D3357894-F047-4D11-98E5-618C0ED6ABA0Q42282480-577F7E2B-ED6C-4A0D-8695-0593C9E30774Q47943718-B70AF030-EA83-40C8-9A04-9A0A443419BBQ48308026-E2916D0B-3CFD-49BC-9365-DDC2358CA24EQ50036781-F01BF217-90FD-4614-B6C2-D1DBE4627236Q50871327-F19EDB98-327B-4A09-A3FD-E72F3CCDD596Q51080164-A32E1B3D-FF63-434E-9A79-E15BA056F6B6
P2860
Prediction of hepatic clearance in human from in vitro data for successful drug development.
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Prediction of hepatic clearanc ...... r successful drug development.
@ast
Prediction of hepatic clearanc ...... r successful drug development.
@en
type
label
Prediction of hepatic clearanc ...... r successful drug development.
@ast
Prediction of hepatic clearanc ...... r successful drug development.
@en
prefLabel
Prediction of hepatic clearanc ...... r successful drug development.
@ast
Prediction of hepatic clearanc ...... r successful drug development.
@en
P2093
P2860
P1433
P1476
Prediction of hepatic clearanc ...... r successful drug development.
@en
P2093
Masato Chiba
Yasuyuki Ishii
Yuichi Sugiyama
P2860
P2888
P304
P356
10.1208/S12248-009-9103-6
P407
P577
2009-04-30T00:00:00Z
P5875
P6179
1014694082